The quality of laboratory analytical performance required to support medical decision-making has been defined in four major ways: (a) by the analytical variance of the state of the practice; (b) by the total variance, including analytical and biologicalvariability; (c by the loss of diagnostic efficiency attributable to analytical error; and (d) by medical-usefulness criteria. From the federal government's perspective, the answer to the question "How good must a laboratory test result be to be medically relevant?" must take into account the clinical context of the test, with accompanying concerns about access, timeliness, and cost, as well as limits for precision and accuracy in the analytical process and the frequency and potential patient-care impact of error in the pre-and postanalytical steps of the total testing process. Therefore, medically relevant goals should encompass not only analytical precision and accuracy but also goals to provide access to clinicallyeffective tests and to reduce errors in the total testing process that can lead to medically misleading information. 
maintaining timely access to testing at a reasonable cost while ensuring that all laboratories have personnel with the technical ability and skills to provide quality results.
Despite the diligent efforts of professional organizations, industry, academia, and governmental agencies to provide the information needed to reassure the public that laboratory testing results are in general highly accurate and reliable, the perception of problems with laboratory testing remain. Thus far, one of the handicaps to changing this public perception has been our inability to demonstrate a clear linkage between traditional measures to assure laboratory test quality, such as proficiency testing (PT), quality control (QC), and quality assurance (QA), and patient outcome. Establishing medically relevant goals for the analytical accuracy and precision of test results as well as processes to eliminate or reduce the number of mistakes in the preand postanalytical phases of testing should enhance our ability to link PT, QC, and QA activities with patient outcomes and justify our reliance on these measures to ensure the accuracy and reliability of the complex process of laboratory testing.
Much of the emphasis in CLIA '88 rests on the recognition that the laboratory world now includes not only hospitals and referral laboratories, but many other testing environments, each of which requires assurance of the quality of patient testing. The successful application of QC to ensure that a laboratory's goals for test precision are met and of external QA and PT to ensure test accuracy goals are met forms the cornerstone of CLIA. In addition, QA, which is addressed by one of the shortest sections of the CLIA regulations, recognizes PT, QC, and other factors as important features in maintaining reliable patient testing. The federal government, taking into account the constraints imposed by the law and >60 000 comments, has attempted to apply logic and science to the greatest extent possible in developing regulatory requirements. For example, in the area of PT, the Centers for Disease Control and Prevention (CDC) has for at least the last 15 similar program (31) , which allows laboratories to determine how their internal operations compare with those of similar facilities, seems essential to ensure that standards of practice in nonanalytical phases of the testing process are being appropriately met. In a recent CAP Q-Probe study (32) of blood-bank QA practices, in which the testing process was divided into 24 discrete steps, with each step representing an area for which a testing mistake could occur, 96 of 1328 facilities had an active system to monitor all 24 steps. Of -64 000 testing process mistakes that were detected and corrected by these facilities, 52% occurred in preanalytical steps, 43% in postanalytical steps, and 5% during the analytical steps. The consequences of these mistakes on patient care were not determined.
Conclusions
Are we ready to set medically relevant goals for the precision and accuracy of laboratory tests in the US? Are such goals necessary? Can they be kept consistent with the current standards of medical practice? Most importantly, will the availability of agreed-upon goals improve patient care?
On the basis of the nation's experience with the National Cholesterol Education Program, we can answer yes to all of these questions for cholesterol testing. Perhaps our accomplishments with cholesterol can be extended to include other laboratory tests.
Unfortunately, successful definition of medically relevant goals for a laboratory test is not sufficient to ensure its effective use for patient care. Reducing the risks to patients of inaccurate or imprecise results will require emphasizing improvements in the entire process of laboratory testing, not just the analytical phase of the process. Therefore, although medically relevant goals for analytical accuracy and precision would be helpful in setting more-realistic requirements for PT and QC activities, more than that is needed to capture and correct the majority of mistakes in the laboratory testing process. To capture and correct these mistakes in a timely and cost-effective manner before they affect patient care requires a focus on obtaining and maintaining accuracy and reliability throughout the testing process. How can we achieve the broader goal of ensuring that laboratory data are medically relevant throughout the testing process? Certainly, medically relevant goals can and should be defined for the analytical phase of testing to permit realistic assessments of PT and QC data. Evaluation of both the quantitative result and its accompanying clinical interpretation could help identify laboratories with inaccurate and imprecise results and reference intervals. In addition, norms should be established within each institution based on the frequency of nonanalytical mistakes in the total testing process over a specffic time interval. Such internal norms might be compared with those of other institutions with similar complexity of operations and clinical contexts of testing. These norms would permit a facility to identify areas most in need of improvement and allow the steps taken to improve testing performance to be measured. all along has been that we are talking about rare events. In fact, when trying to put together our CLIA studies, we recognized that we think we will be looking for very rare occurrences, and it is going to be very difficult for us to find anything.
In terms of your second point, it depends on where in the testing process that the mistakes occurred and whether they were actually corrected before medical management.
In some cases, it was difficult to discern whether they had been corrected first. I'm not sure it is as high as 99.97%; it is probably 90%. However, I don't know whether these results are representative. Of course, one problem with an error detection system is that you don't know how many errors you missed; some you simply will never find. In the Q-Probe study, all mistakes were detected and corrected. If the majority of laboratory mistakes are not caused by analytical error but are caused by the rest of the system, then trying to correct those mistakes by focusing on proficiency testing will not get us the result we really want: an improvement in the quality of the patient's result and patient testing.
Wiveka Elion-Gerritzen: I have heard many times here that physicians are unaware of analytical, preanalytical, and biological variability.
People have been saying and writing this for many years, and yet I know of no proof for these statements.
In my study, I interviewed clinicians and, for example, for the lower limit of normal for potassium and the upper limit of normal for calcium I registered zero differences between the limit of normal and the action value. In these cases, physicians took action exactly at the limit of normal or even before the limit of normal was reached-which did not mean they were unaware of variability of laboratory results. A physician when making a decision will consider the seriousness of the illness, being, for example, much more keen on liver function tests when liver metastases are suspected than when alcohol abuse is at stake. Medical action will be indicated by the availability of therapy, the chance of success, and the risk taken when the physician does not do anything.
The first action is very often to repeat the test. I think physicians are very well aware of analytical, preanalytical, and biological variability-and also of our blunder rate! For instance, consider the variability among physicians in assessing prognosis in a given situation. In one study asking physicians about 10-year survival after heart valve implantation, prognostic estimates ranged from 5% to 95%. Clearly the real probability of survival is a single finite number, even if we allow for sampling variability about that number. Thus, a realistic prognostic estimate can be made, even though many physicians would not make it. The same considerations apply to therapeutic decisions. For instance, the frequency of hysterectomy varies threefold between cities, but no explanation for these differences has been found. Therefore, optimal medical strategies cannot be derived from a general analysis of physician's behavior. Rather, the scientific basis that should underlie medical decisions must be analyzed. This is indeed the concept that underlies recent federal legislation for a centralized effort to develop practice parameters for outcome assess-
